NCT02101164 Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease Status WITHDRAWN Phase PHASE4
NCT02099461 Effect of Denosumab on Cellular Biomarkers in the Human Breast Status COMPLETED Phase PHASE1
NCT02049866 Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP Status COMPLETED Phase PHASE2
NCT01973569 AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment Status COMPLETED Phase NA
NCT01951586 Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT01869686 Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose Status COMPLETED Phase PHASE1
NCT01864798 A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer Status TERMINATED Phase PHASE2
NCT01824342 Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer Status COMPLETED Phase PHASE3
NCT01799798 Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab Status COMPLETED Phase PHASE2
NCT01753856 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Status COMPLETED Phase PHASE4
NCT01734824 Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo Status SUSPENDED Phase PHASE4
NCT01732770 Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Status COMPLETED Phase PHASE4
NCT01652690 Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice Status COMPLETED Phase N/A
NCT01630941 Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty Status COMPLETED Phase PHASE2
NCT01624766 Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Status COMPLETED Phase PHASE1